Protective immunity to DENV2 after immunization with a recombinant NS1 protein using a genetically detoxified heat-labile toxin as an adjuvant  by Amorim, Jaime Henrique et al.
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The  dengue  virus  non-structural  1  (NS1)  protein  contributes  to  evasion  of  host  immune  defenses  and
represents  a target  for immune  responses.  Evidences  generated  in  experimental  models,  as  well  as  the
immune  responses  elicited  by infected  individuals,  showed  that  induction  of  anti-NS1  immunity  corre-
lates  with  protective  immunity  but  may  also  result  in  the  generation  of cross-reactive  antibodies  that
recognize  platelets  and  proteins  involved  in  the  coagulation  cascade.  In  the  present  work,  we evaluated
the  immune  responses,  protection  to type  2  dengue  virus  (DENV2)  challenges  and  safety  parameters  in
BALB/c  mice  vaccinated  with  a recombinant  NS1  protein  in  combination  with  three  different  adjuvants:
aluminum  hydroxide  (alum),  Freund’s  adjuvant  (FA)  or a genetically  detoxiﬁed  derivative  of  the heat-
labile  toxin  (LTG33D),  originally  produced  by  some  enterotoxigenic  Escherichia  coli  (ETEC)  strains.  Mice
were  subcutaneously  (s.c.)  immunized  with  different  vaccine  formulations  and  the  induced  NS1-speciﬁc
responses,  including  serum  antibodies  and  T cell responses,  were  measured.  Mice  were also  subjected
to  lethal  challenges  with  the  DENV2  NGC  strain.  The  results  showed  that  maximal  protective  immunity
(50%)  was  achieved  in mice  vaccinated  with  NS1 in  combination  with  LTG33D. Analyses  of the  NS1-speciﬁc
immune  responses  showed  that  the  anti-virus  protection  correlated  mainly  with  the  serum  anti-NS1
antibody  responses  including  higher  avidity  to the  target  antigen.  Mice  immunized  with  LTG33D elicited
a  prevailing  IgG2a  subclass  response  and  generated  antibodies  with  stronger  afﬁnity  to  the  antigen  than
those  generated  in  mice  immunized  with  the  other  vaccine  formulations.  The  vaccine  formulations  were
also  evaluated  regarding  induction  of deleterious  side  effects  and,  in  contrast  to  mice  immunized  with
the  FA-adjuvanted  vaccine,  no  signiﬁcant  hepatic  damage  or enhanced  C-reactive  protein  levels  were
detected  in  mice  immunized  with  NS1  and  LTG33D. Similarly,  no  detectable  alterations  in bleeding  time
and  hematological  parameters  were  detected  in  mice  vaccinated  with  NS1  and  LTG33D. Altogether,  these
results  indicate  that  the  combination  of  a  puriﬁed  recombinant  NS1  and  a nontoxic  LT  derivative  is  a
promising  alternative  for the  generation  of  safe and effective  protein-based  anti-dengue  vaccine.. Introduction
Dengue fever is a common mosquito-borne viral disease that
epresents a major worldwide public health concern, particularly
or those living in tropical countries and people traveling to these
ones. Globally, more than 2.5 billion people are exposed to dengue
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amento  de Microbiologia, ICB II, Universidade de São Paulo, Av. Prof. Lineu Prestes,
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virus (DENV) infection in endemic areas, and thousands of them
die each year [1]. The spread of the virus observed over the last
25 years and the growing numbers of the more serious clini-
cal cases, the dengue hemorrhagic fever (DHF) and the dengue
shock syndrome (DSS), underscore the need for an effective anti-
dengue vaccine [2,3]. Efforts to develop a DENV vaccine have
mainly focused on attenuated or inactivated virus-based vaccine
formulations. Despite the success of similar vaccine approaches in
controlling other Flaviviruses, such as the yellow fever virus and the
Open access under the Elsevier OA license.Japanese encephalitis virus, and several clinical trials conducted
using most promising formulations, an effective dengue vaccine
is still not available for human use [4–6]. Inefﬁcient induction of
protective immunity to the four viral types (DENV1, 2, 3 and 4),
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nd safety concerns involving induction of antibody dependent
nhancement (ADE), a mechanism believed to be involved in DHF
nd DSS occurrence, and deleterious cross-reactive reactions are
he most relevant obstacles for the development of an effective
engue vaccine based on live virus particles [7].
DENV subunit vaccine formulation, based either on DNA or
uriﬁed recombinant proteins represent safer alternatives to atten-
ated or recombinant viruses [3]. The most studied subunit vaccine
pproaches for dengue virus are based on either the complete
nvelope glycoprotein or fragments of this protein [1,8–11]. Immu-
ization of mice with the DENV non-structural protein 1 (NS1),
ither as puriﬁed protein or encoded by DNA vaccines, have
lso shown promising results [12–16]. The DENV NS1 is a highly
mmunogenic 46–50 kDa glycoprotein expressed by infected cells
oth as a secreted oligomeric form and as a membrane-associated
rotein [17,18]. Although the precise functions of NS1 in the infec-
ion cycle remains unclear, it is accepted that this protein has an
mportant role in the viral pathogenesis interfering with the com-
lement activation cascade [19].
Mice immunized with NS1-based vaccines, particularly those
ncoded by DNA vaccines, develop protective immunity that
nvolves both antibody and T cell responses [14–16]. In contrast, the
rotective immunity generated in mice immunized with puriﬁed
S1 protein alone seems to be based mainly on the generation of
ntigen-speciﬁc serum antibodies [12,13,20,21]. However, further
tudies have raised concern regarding the safety of NS1 as a vac-
ine antigen. Anti-NS1 antibodies detected in infected subjects or
licited in vaccinated mice may  cross-react with proteins exposed
n the surface of platelets, endothelial cells and proteins involved
n the blood coagulation cascade, which may  lead to vascular dam-
ges, thrombocytopenia and hemorrhage [22–27].
Adjuvants are key components of most vaccine formulations,
articularly those based on puriﬁed proteins. Besides reducing the
mount of antigen and number of doses required to achieve a spe-
iﬁc immune response, adjuvants are modulators of the adaptive
mmunity but may  lead to deleterious inﬂammatory reactions [28].
uring decades aluminum hydroxide (alum) has been the only
djuvant alternative for human use. Nonetheless, new adjuvant
lternatives became recently available for human use, such as MF59
nd ASO4 [28,29]. Clearly, the identiﬁcation of safe and effective
djuvants represents a key step on the development of new vaccine
ormulations.
The heat-labile enterotoxins (LT) are AB-type toxins produced
y some enterotoxigenic Escherichia coli (ETEC) endowed with
owerful adjuvant effects on both humoral and cellular immune
esponses to co-administered antigens [30,31]. Due to the intrin-
ic toxic effects of mucosal-delivered LT, attenuated or nontoxic
T mutants with preserved adjuvanticity have been generated
y site-directed mutagenesis [31]. LTK63, LTR72 and LTR192G, with
mino acid changes in the A subunit, and LTG33D with a single
oint mutation at the B subunit, are the best characterized LT
erivatives regarding both biological effects and immunological
ctivities [32–35]. Replacing the glycine at position 33 of the B
ubunit with aspartate (G33D) abolishes LT binding to the GM1
anglioside receptor and, consequently, reduces the toxin adjuvan-
icity following delivery via oral route [33]. Nonetheless, parenteral
dministration of LTG33D has been shown to preserve the adjuvant
roperties of the protein for both B and T cell responses against
o-administered antigens without induction of deleterious inﬂam-
atory reactions [35].
In  this study, we evaluated the efﬁcacy of anti-DENV vac-
ines based on a recombinant NS1 protein derived from type 2
ENV (DENV2) generated in a prokaryotic expression system with
reserved structural and immunological features [36]. Vaccine for-
ulations based on the recombinant NS1 protein admixed with
hree different adjuvants, alum, Freund’s adjuvant [FA] and LTG33D, 30 (2012) 837– 845
were tested in mice trough parenteral administration. The results
demonstrated that the adjuvant choice strongly affects both the
immunogenicity and, more relevantly, the induction of protective
immune responses in vaccinated mice. The results also indicate
that the combination of recombinant NS1 and LTG33D generates
protective antibody responses without the induction of signiﬁcant
deleterious side effects.
2.  Materials and methods
2.1.  Ethics statement
All  handling procedures and experiments involving mice were
approved by the committee on the ethical use of laboratory animals
from the Institute of Biomedical Sciences of São Paulo University,
in accordance with the recommendations in the guidelines for the
care and use of laboratory animals of the National Committee on
the Ethics of Research (CONEP).
2.2.  Virus and cell lines
The  dengue 2 virus (DENV-2) strain New Guinea C (NGC) was
used in the challenge assays [16,37,38]. DENV-2 NGC strain prop-
agation was  carried out in Vero cells cultured in medium 199 with
Earle salts (E199) buffered with sodium bicarbonate (Sigma, USA),
supplemented with 10% fetal bovine serum (FBS).
2.3. Generation of the mutated eltG33D gene and puriﬁcation of
the recombinant NS1 and LTG33D
The etlG33D gene, mutated at amino acid position 33 of the B
subunit, was  generated by overlap extension splicing using the
elt gene sequence of the ETEC H10407 strain [39,40]. The exter-
nal primers used were 5′-CACGGTACCTCTTTCTTTATCG-3′ (KpnI
restriction site underlined) and 5′-GGTTCTCTGCAGAGACATGC-3′
(PstI restriction site underlined). The internal primers respon-
sible for introducing the mutation leading to the amino acid
replacement G33D were 5′-GAATCGATGGCAGATAAAAG-3′ and
5′-CTCTTTTATCTGCCATCGAT-3′. The ampliﬁcation reactions were
performed as described previously [39]. The resulting fragment was
puriﬁed using a gel puriﬁcation kit (IlustraTM GFXTM PCR DNA and
Gel Band Puriﬁcation Kit, GE Healthcare), digested with restriction
enzymes and then ligated into the corresponding KpnI and PstI sites
of the linearized pBSPKS (−) vector [41], generating the recombi-
nant plasmid pKSLTG33D. The pKSLTG33D plasmid was subsequently
introduced into chemically competent E. coli DH5 bacteria. One
bacterial clone carrying the correct plasmid was named LDVLTG33D.
The correct sequence of the etxG33D gene was conﬁrmed by DNA
sequencing. LTG33D was puriﬁed by galactose-afﬁnity chromatog-
raphy following a standard LT puriﬁcation procedure [40]. Brieﬂy,
the LDVLTG33D lineage was cultivated in Terriﬁc Broth (TB) [42],
containing 200 g/ml of ampicillin, overnight at 37 ◦C in an orbital
shaker set at 200 rpm. Cells were suspended at a 10% (w/v)
concentration in TEAN buffer (50 mM Tris; 1 mM EDTA; 3 mM
azide-Na and 200 mM NaCl; pH 7.5) and lysed by mechanical
shearing in an APLAB-10 homogenizer (ARTEPEC¸ AS, Brazil). The
soluble extract was applied into a XK 16/20 column (GE Amer-
shan Biosciences) containing immobilized d-galactose gel (Pierce),
extensively washed with TEAN buffer prepared with pyrogen-
free water, and subsequently eluted with TEAN buffer containing
0.3 M galactose. The ﬁnal amount of LTG33D was determined in
GeneQuant spectrophotometer (GE Amershan Biosciences). The
puriﬁcation of the DENV2 NS1 recombinant protein was achieved
after denaturation/refolding steps of the protein expressed in bac-
terial cells and afﬁnity chromatography, as previously reported
J.H. Amorim et al. / Vaccine 30 (2012) 837– 845 839
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36]. Endotoxin levels in LTG33D and NS1 preparations were deter-
ined with the Chromogenic Limulus Amebocyte Lysate assay
Cambrex Bio Science) [43].
.4. ELISA and immunoblot analyses of NS1 and LTG33D
The recombinant NS1 and LTG33D proteins were analyzed for
urity and antigenicity by SDS-PAGE and Western blot. Protein
liquots (2 g) were sorted in 15% polyacrylamide gels after heat
reatment (100 ◦C for 10 min) or kept at room temperature with
ample buffer [36,44]. Standard ELISA assays were performed as
reviously described [36,45]. The recombinant NS1 protein was
ested in the non-heated or in heat-denatured state with serum
amples collected from a DENV2-infected individual (kindly sup-
lied by Dr. Bergman M.  Ribeiro, Brasília University, FD, Brazil).
 serum sample generated after immunization of mice with
eat-denatured (100 ◦C for 10 min) NS1 in FA after the same immu-
ization regimen described bellow (Fig. 1), was used in order to
emonstrate that heat denaturation of the recombinant NS1 did
ot affect binding to ELISA plates. GM1-ELISAs using puriﬁed LTG33D
nd parenteral LT derived from ETEC H10407 strain were carried
ut as reported previously [40].
.5. Immunization regimens
BALB/c mice, 4–6 weeks old, were divided into groups (n = 6 for
mmune response monitoring and n = 10 for the virus challenges)
nd submitted to an immunization regimen comprising four doses
f the tested vaccine formulations administered via the subcuta-
eous (s.c.) route on days 0, 14, 21 and 28 (Fig. 1). Mice were
noculated with 10 g of NS1 alone or the same amount of NS1
ombined with: 1.25 g of alum (Rehydragel from Reheis), accord-
ng to a standard procedure [46] that results in 99.7% binding of
he protein to the solid matrix, Freund’s adjuvant (50%, v/v), with
he complete adjuvant in the ﬁrst dose and the incomplete formu-
ation in the subsequent injections; or 1 g of LTG33D. The amount
f LTG33D used in the vaccine formulations was based on previ-
usly reported results [36]. Sham-treated mice were injected with
hosphate buffered saline (PBS). Mice were bled at the retro-orbital
lexus before each vaccine dose and one week after the last admin-
stration. Serum samples were individually tested for reactivity to
S1, pooled and stored at −20 ◦C for subsequent analyses.
.6. Determination of anti-NS1 serum antibody responses
Mouse sera were tested individually for the presence of NS1-
peciﬁc antibodies by ELISA, as previously described [45]. Brieﬂy,
axiSorp plates (Nunc) were coated with 0.2 g per well of the
ecombinant NS1 protein in 100 L PBS and blocked for 1 h at 37 ◦C
ith 5% skim milk in 0.05% Tween-20–PBS (PBST). Serum sam-
les were serially diluted and added to wells previously washed
ith PBST. After 1 h at room temperature, plates were washed with
BST and incubated with goat anti-mouse immunoglobulin (whole
gG isotype, IgG1 or IgG2a subclasses) conjugated with horseradish
eroxidase (Southern Biotechnology) for 1 h at room temperature.
eactions were measured at A490 nm with ortho-phenylenediamine
ihydrochloride (Sigma) and H2O2 as substrate and with a 2 Nith the tested NS1-based vaccine formulations.
H2SO4 stopping solution. Titers were established as the recipro-
cal of serum dilution which gave an absorbance two-fold higher
than the SD values of the respective non-immunized samples.
2.7.  Determination of cytokine-secretion patterns
One week after the last immunization, mice were euthanized
and their spleens were harvested. Splenocytes were pooled and
seeded (5 × 105 cells per well) in 12-well plates (Nunc) in RPMI
supplemented with 10% FBS, 2 mM l-glutamine, 1 mM sodium
pyruvate, 2 mM nonessential amino acids, 10 mM HEPES buffer and
50 units/ml of penicillin–streptomycin. Cells were then incubated
with puriﬁed NS1 at 37 ◦C with 5% CO2 for 48 h. Culture super-
natants were collected and tested individually for IFN- and IL-5
by ELISA, according to the manufacturer’s instructions (BD Bio-
science), as markers for activation of type 1 and type 2 Th responses,
respectively.
2.8. Lethal challenges with DENV2
Two weeks after the ﬁnal vaccine dose, mice were challenged
with the DENV2 NGC strain, a mouse-adapted virus strain, as pre-
viously described [16,37,38]. Animals were anesthetized with a
mixture of ketamine and xylazine [47] and intra cranially (i.c.)
challenged with 30 l of E199 medium supplemented with 5%
FBS containing 4.32 log10 PFU of DENV-2, which corresponds to
approximately 3.8 LD50. Animals were monitored for 21 days, and
mortality and morbidity rates were recorded.
2.9. ELISPOT
The IFN- ELISPOT assay was  performed as previously described
[40]. Two  weeks after the immunization regimen, cells derived
from spleens of vaccinated mice were placed (2 × 105 cells/well)
in a 96-well micro titer plate (MultiScreen, Millipore) previously
coated with 10 g/ml of rat anti-mouse INF- monoclonal anti-
body (mAb) (BD Pharmingen). Cells were cultured at 37 ◦C with
5% CO2 for 18 h in the presence or absence of 5 g of the H-2d-
restricted CD8+ T cell-speciﬁc epitope AGPWHLGKL (NS1265–273),
a highly conserved epitope among the DENV serotypes [48]. As a
positive control, cells from all groups were pooled and cultured
in the presence of concanavalin A, as previously described [49].
After incubation, cells were washed away, and plates were incu-
bated with a biotinylated anti-mouse INF- mAb  (BD Pharmingen)
at a ﬁnal concentration of 2 g/ml at 4 ◦C. After 16–18 h, the plates
were incubated with diluted peroxidase-conjugated streptavidin
(Sigma–Aldrich). The spots were developed using diaminobenzi-
dine (DAB) substrate (Sigma–Aldrich) and counted with a stereo
microscope (model SMZ645, Nikon).
2.10. In vivo evaluation of NS1-speciﬁc cytotoxic CD8+ T
lymphocytesThe in vivo assessment of the cytotoxic activity of CD8+ T
cells induced in the different immunization groups was  carried
out as previously described [40]. Splenocytes from naive mice
were stained with 0.5 M or 5 M carboxyﬂuorescein diacetate
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uccinimidyl ester (CFSE) (Invitrogen) for 15 min  at 37 ◦C. The cells
abeled with 5 M of CFSE were then pulsed with the NS1265–273
ligopeptide (AGPWHLGKL) [48,50]. Both CFSE-labeled cell popula-
ions, NS1265–273 pulsed or not, were transferred intravenously to
accinated mice (2 × 107 cells of each population). One day later,
he inoculated animals were euthanized and individual spleens
ere isolated to identify the two CFSE-labeled cell populations by
ultivariant FACScan analyses (FACSCalibur from BD Biosciences).
he percentages of speciﬁc target cell killing were calculated for
ach individual by comparing the reduction of peptide-pulsed cells
elative to that of the non-pulsed cells.
.11. NS1-antibody afﬁnity determination
The afﬁnity of anti-NS1 antibodies was assessed by the ammo-
ium thiocyanate elution-ELISA method, as previously described
51]. The procedure was similar to that of the standard ELISA with
he inclusion of an extra step. After incubation with the pooled
era diluted according to titers obtained by ELISA, the plates were
ashed and ammonium thiocyanate, diluted in PBS, was added to
he wells in concentrations ranging from 0 to 8 M.  Plates were main-
ained at room temperature for 15 min. The percentage of antibody
inding was calculated as the OD490 in the presence of ammo-
ium thiocyanate × 100, divided by the OD490 in the absence of
mmonium thiocyanate.
.12.  Monitoring tissue damages in vaccinated mice
Individual serum samples were used to determine glutamic
xalacetic transaminase (GOT), glutamic pyruvic transaminase
GPT) and C-reactive protein (CRP) levels, using analytical kits as
ecommended by the supplier (Bioclin, Brazil).
.13. Bleeding time and blood cell analyses
Bleeding time was measured at day seven following the fourth
accine dose by creating a 3 mm  incision at the tail tip. Blood
roplets were collected on ﬁlter paper every 30 s for the ﬁrst 3 min,
nd every 10 s thereafter. Bleeding was considered to be ﬁnished
hen the collected blood spot’s diameter was less than 0.1 mm
22]. Complete blood cell counts were also taken at this time.
hole blood samples were collected in micro tubes containing
.37 M EDTA. For hematocrit determination, micro capillaries were
lled with blood samples, centrifuged at 5000 rpm for 5 min  and
roperly positioned in a packed cell volume table for hematocrit
coring [52]. Red blood cell (RBC) and white blood cell (WBC) counts
ere carried out using a Neubauer chamber. Platelet numbers were
etermined according to the Fonio’s method and neutrophil and
ymphocyte differentiation was performed visually using a phase
ontrast microscope [52], (Eclipse E200 model, Nikon).
.14.  Statistical analyses
Statistical  analyses were carried out using ANOVA and a sub-
equent Bonferroni’s Multiple Comparison test. For survival and
orbidity rates, Mantel–Cox and Gehan–Breslow–Wilcoxon tests
ere performed. Statistical signiﬁcance was set as p < 0.05.
. Results
.1. Generation of puriﬁed NS1 and LTG33DBoth NS1 and LTG33D were produced by recombinant E. coli cells
nd tested for antigenicity and/or biological activity. The recom-
inant DENV2 NS1 protein was obtained mainly as dimers, as
emonstrated after sorting in polyacrylamide gels (Fig. 2A). As 30 (2012) 837– 845
demonstrated  previously [36], the recombinant NS1 preserved, at
least partially, some features of the native virus protein. In addition,
the recombinant NS1 retained, at least in part, the antigenicity of
the native protein as demonstrated by the reactivity of the recombi-
nant protein with a serum sample collected from a DENV2 infected
patient (Fig. 2B). The reactivity of the anti-NS1 serum sample
was drastically reduced after heat denaturation of the recombi-
nant protein, which indicates that conformational epitopes of the
protein were lost. To demonstrate that the heat-denaturation treat-
ment did not interfered with the binding of protein to the ELISA
plates, the protein samples were reacted with a mouse serum
raised in mice immunized with a heat-denatured NS1 (Fig. 2B).
In contrast to antibodies raised in the DENV2 infected subject,
this serum sample did not show any reduction in the recogni-
tion of the heat-denatured NS1 in ELISA, which indicated that
denaturation of the recombinant protein did not affect the bind-
ing of the protein to the plate. The puriﬁed recombinant LTG33D
protein encompassed both the A and B subunits, as detected
in polyacrylamide gels (Fig. 2C). As expected, the recombinant
protein showed reduced binding to the GM1 ganglioside when
compared to the parental toxin (Fig. 2D), as previously reported
[35]. Both NS1 and LTG33D preparations had low residual LPS con-
centrations (50 EU/mg and 82 EU/mg, respectively). The amount of
endotoxin administered in each mice was 0.5 endotoxin units/dose
and 0.582 endotoxin units/dose in samples containing NS1 alone
or NS1 and LTG33D, respectively, which did not interfere with the
induced immune response of vaccinated mice (data not shown)
[43].
3.2. Immune responses in mice immunized with NS1-containing
vaccines
To  determine the immunogenicity of the recombinant NS1 pro-
tein, BALB/c mice were s.c. immunized with the puriﬁed protein
admixed with one of three different adjuvants (alum, FA or LTG33D)
using a four-dose vaccine regimen (Fig. 1). Under the testing con-
ditions, 99.7% of the NS1 protein remained bound to the alum salts,
while vaccines adjuvanted with FA or LTG33D were prepared accord-
ing to previously reported conditions [35,46]. Measurement of the
serum anti-NS1 IgG responses showed that mice immunized with
three or four doses of NS1 admixed with LTG33D elicited stronger
responses than those immunized with vaccines containing alum
or FA (p < 0.001). In addition, assessment of the serum IgG sub-
class responses showed that mice immunized with NS1 and alum
produced low IgG2a levels (IgG1/IgG2a ratios of 83) while those
immunized with NS1 in combination with FA or LTG33D elicited
more balanced subclass responses with IgG1/IgG2a ratios of 4.3
and 1.8, respectively. A similar response proﬁle was observed when
assessing IFN- and IL-5 secretion in the culture supernatants
of NS1-stimulated spleen cells collected from mice immunized
with the three different vaccine formulations. As demonstrated
in Fig. 3C, the IFN-/IL-5 ratio (5.74) detected in mice immu-
nized with NS1 and LTG33D was  higher than the ratios detected
in mice immunized with NS1 combined with alum or FA (0.32
and 3.52, respectively). Interestingly, mice immunized with LTG33D
and NS1 generated serum antibodies with enhanced avidity to the
NS1 protein (Fig. 3D). The concentration of ammonium thiocyanate
required to dissociate 50% of the antibodies bound to NS1 in sera
collected from mice immunized with LTG33D was approximately
two and four-fold higher than the amounts of the reagent required
to dissociate anti-NS1 antibodies generated in mice treated with
FA and alum, respectively.We  also measured the induced T cell responses in mice immu-
nized with the different NS1-based vaccine formulations. As shown
in Fig. 3E and F, the tested vaccine formulations induced low anti-
NS1 CD8+ T cell responses in mice, as measured by the numbers of
J.H. Amorim et al. / Vaccine 30 (2012) 837– 845 841
Fig. 2. Electrophoretic patterns and biological activities of the recombinant NS1 and LTG33D. (A) Puriﬁed refolded NS1 protein detected in a SDS-polyacrylamide gel (lanes 1
and  2) and immunoblot (lanes 3 and 4). Aliquots of the puriﬁed protein (1 g) were sorted in a 15% polyacrylamide gel stained with Coomassie brilliant blue (lanes 1 and
2)  or transferred to a nitrocellulose membrane and reacted with serum collected from mice immunized with a DNA vaccine encoding the DENV2 NS1 protein (lanes 3 and
4).  Heat-denatured samples (lanes 2 and 4) were obtained following protein incubation at 100 ◦C for 10 min  M,  molecular weight markers (band sizes indicated at the left
side).  (B) Reactivity of the intact recombinant NS1 protein with a serum sample collected from a DENV2-infected patient (open squares). Heat treatment (100 ◦C for 10 min)
abolished the antigenicity of the protein as demonstrated by the lack of reactivity with the serum antibodies (closed squares). The control serum generated in mice against
the  heat-denatured form of the recombinant NS1 reacted in the same degree with the non-heated (closed circles) and the heated (open circles) forms of the antigen, showing
that  heat treatment did not affect NS1 binding to the plate. (C) Puriﬁcation of the LTG33D by galactose-afﬁnity chromatography. Protein samples (1 g) were sorted in 15%
polyacrylamide gels and stained with Coomassie brilliant blue (lanes 1 and 2) or reacted with an anti-LT mouse serum in a Western blot (lanes 3 and 4). Heat-denatured
samples (lanes 2 and 4) were obtained following incubation of the protein at 100 ◦C for 10 min M,  molecular weight markers (band sizes indicated at the left of the ﬁgure).
(D) GM1-ELISA of the puriﬁed non-toxic LTG33D and the parental non-mutated LT1. GM1-binding mediated by the B subunit was  ablated by the G33D B subunit mutation in
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S1-speciﬁc IFN- secreting cells. In addition, experiments carried
ut with mouse splenocytes labeled with CFSE and pulsed with the
HC-I-restricted CD8+ T cell speciﬁc AGPWHLGKL peptide showed
hat the induced antigen-speciﬁc cytotoxic responses induced in
nimals submitted to the different immunization regimen were low
ut with higher responses detected in mice immunized with NS1
dmixed with FA or LTG33D regarding mice immunized with NS1
djuvanted with alum.
.3.  Protective responses induced in mice immunized with
S1-based vaccines
Protective  anti-DENV2 responses were measured in mice
mmunized with the different vaccination formulations following
dministration of a lethal i.c. challenge with the DENV2 NGC virus
train. As demonstrated in Fig. 4A, mice vaccinated with NS1 and
TG33D showed a 50% protection level. A lower but not statistically
ifferent result was observed in mice immunized with NS1 and FA
40% protection). In contrast, no protection was observed in mice
mmunized with NS1 combined with alum, non-adjuvanted NS1 or
ham-treated animals. We  also monitored the DENV2-associated
orbidity and, as indicated in Fig. 4B, and mice immunized with
S1 combined with LTG33D or FA showed similar degree of partial
imb paralysis (80% and 70% of the vaccinated mice, respectively).As  expected, all mice immunized with NS1 and alum, NS1 or sham-
treated animals showed severe limb paralysis before death by virus
encephalitis.
3.4. Safety evaluation of the NS1-based vaccines
Previous studies indicated that anti-NS1 antibodies may  recog-
nize cross-reacting epitopes on platelets and endothelial cells, as
well as proteins involved in the coagulation pathway, provoking
hematological disturbances [22–26]. As a ﬁrst step to investigate
the safety of the NS1-based vaccine formulations, we  measured
biochemical markers of hepatic function and nonspeciﬁc tissue
inﬂammatory reactions in vaccinated mice. As shown in Fig. 5A
and B, GOT and GPT enzyme markers were signiﬁcantly increased in
mice immunized with NS1 admixed with FA but not in mice immu-
nized with NS1 and LTG33D. Similarly, C-reactive protein levels
were, on average, higher in mice immunized with NS1 and FA than
in mice immunized with NS1 and LTG33D or in sham-treated mice.
These results indicate that incorporation of FA, but not LTG33D, could
induce mild inﬂammatory reactions among the vaccinated mice. In
a second step, we  determined hematological parameters that could
indicate disturbances induced by the vaccine formulations adju-
vanted with LTG33D. For that purpose mice immunized with NS1
and LTG33D were monitored for hematocrit values, bleeding time,
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Fig. 3. Immune responses in mice immunized with NS-1-based vaccine formulations. (A) Serum IgG anti-NS1 responses detected in BALB/c mice immunized with puriﬁed
NS1  in combination with different adjuvants. Mouse groups (n = 6) were s.c. immunized with four doses of 10 g of puriﬁed NS1 admixed with alum (1.25 g), FA (1:1, v/v),
or  LTG33D (1 g). The anti-NS1 antibody responses were measured one week after each vaccine dose. Mouse groups immunized with non-adjuvanted NS1 and sham-treated
mice were also included as controls to determine the adjuvant effects and non-speciﬁc reactions, respectively. Anti-NS1 titers were represented as reverse values of the
maximal dilutions yielding A490 nm > 0.1. Values are based on individual responses and expressed as means ± SD. Mice immunized with three or four doses of NS1 admixed
with LTG33D elicited stronger responses than those immunized with vaccines containing alum or FA (*p < 0.001). (B) Anti-NS1 serum IgG subclasses responses in mice treated
with the different vaccine regimens. Anti-NS1 IgG1 and IgG2a titers were represented as reverse values of the maximal dilutions yielding A490 nm > 0.1. The IgG1/IgG2a ratios
of  each vaccination group are indicated on the top of the ﬁgure. Values were determined using serum pools of each immunization groups. (C) Secreted cytokine responses
measured in culture supernatants of spleen cells collected from mice vaccinated with the different immunization regimens. The INF- and IL-5 values were determined after
stimulation with puriﬁed NS1. INF-/IL-5 ratios are indicated at the top of the ﬁgure. (D) Antigen afﬁnity determination of anti-NS1 antibodies raised in mice treated with
the  different vaccination regimens. Antigen afﬁnity was determined as the ammonium thiocyanate concentration (M)  required to dissociate 50% of antibodies bound to NS1
on  ELISA plates. (E) In vivo NS1-speciﬁc cytotoxic CD8+ T cell activity in mice immunized with different vaccine formulations. Spleen cells collected from naïve mice were
labeled with CFSE and pulsed with the H-2d-restricted CD8+ speciﬁc NS1 epitope AGPWHLGKL (NS1265–273) and subsequently i.v. inoculated in mice immunized with the
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s a stimulatory positive control. Data presented in this ﬁgure represent one of twolatelet counts and leukocyte counting, including neutrophils and
ymphocytes. As indicated in Table 1, no evidence of hematological
isturbance or hemorrhage was observed in mice immunized with
S1 and LTG33D up to seven days after immunization.
ig. 4. Anti-DENV2 protection conferred to mice immunized with NS1-based vaccine for
wo weeks after the last vaccine dose. Survival (A) and morbidity (B) values were monitoto cells labeled only with CFSE, 18 h after administration of the labeled cells in the
llowing in vitro stimulation with the NS1265–273 peptide. Concanavalin A was used
endent experiments.4.  Discussion
In this study, we  tested NS1-based vaccine formulations using
a puriﬁed recombinant protein co-administered with different
mulations. Mice were i.c. challenged with 4.32 log10 PFU of the NGC DENV2 strain
red for 30 days after the virus challenge.
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Fig. 5. Safety evaluation of the tested NS1-based vaccine formulations. (A) GOT, (B) GPT and (C) CRP levels were measured in serum samples collected from mice submitted
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djuvants as an attempt to develop a safe and effective alterna-
ive for the control of dengue virus infection. The recombinant NS1
rotein, despite production in bacterial cells, preserved important
mmunological features of the native protein, including speciﬁc
eactivity with antibodies generated in a DENV-2 infected subject.
n addition to alum and FA, we tested a nontoxic LT derivative,
TG33D, as parenterally delivered adjuvants. Although devoid of the
atural toxicity, the LT derivative showed strong adjuvant effects
egarding induction of anti-NS1 serum antibodies. Mice immunized
ith vaccine formulations adjuvanted with LTG33D showed partial
rotection to lethal encephalitis after challenge with a mouse-
dapted DENV2 strain, similar to that achieved in mice immunized
ith NS1 adjuvanted with FA. However, in contrast to mice immu-
ized with FA, mice immunized with NS1 and LTG33D did not
how any signiﬁcant side effects regarding altered hepatic function
nd unspeciﬁc inﬂammatory reactions. In addition, mice immu-
ized with NS1 and LTG33D did not show any altered hematological
arameters, such as neutropenia, and bleeding tendency. Alto-
ether, these results demonstrated that the combination of NS1 and
TG33D represents a promising alternative for the development of
otentially safe and effective protein-based anti-dengue vaccines.
Parenteral  administration of the recombinant NS1 protein
dmixed with one of three tested vaccine adjuvants (alum, FA and
on-toxic LT derivative) had distinct effects regarding the induction
f antigen-speciﬁc immune responses. Mice immunized with NS1
able 1
ematological analyses of mice immunized with puriﬁed NS1 and LTG33D.
Hematological
parametersb
Immunization groupsa
PBS NS1 (10 g) NS1 (10 g) + LTG33D (1 g)
WBC  7.5 ± 1.28 6.1 ± 2.07 7.47 ± 2.92
NEU 1.5 ± 0.33 1.22 ± 0.37 1.42 ± 0.72
LYM  5.32 ± 0.99 4.52 ± 1.79 5.75 ± 2.24
RBC  6.53 ± 1.72 6.32 ± 2.13 5.48 ± 0.57
HCTc 36.83 ± 0.98 37.17 ± 0.98 37.5 ± 1.05
PLT  1.55 ± 0.35 1.57 ± 0.45 1.38 ± 0.32
BTd 188 ±  46 220 ±  151 195 ± 75
a Six Balb/c mice per immunization group were bled 7 days following the ﬁnal
ose.
b Blood samples were processed to determine white blood cells (WBC), neu-
rophils (NEU), lymphocytes (LYM), red blood cells (RBC), and platelets (PLT)
umbers. WBC, NEU, LYM and PLT counts are given in 103 cells/l. RBC count are
xpressed  in 106 cells/l.
c Hematocrit (HCT) values are given in percentages (%).
d The bleeding times (BT) are expressed in seconds. Data are expressed as the
ean  ± SD of individual measurements. Differences among groups were not seen
fter ANOVA and Bonferroni’s Multiple Comparison test. Results contained in this
able represent one of two independent experiments..05; **p < 0.01. Data presented in this ﬁgure represent one representative result of
in combination with LTG33D showed higher NS1-speciﬁc IgG titers
compared to mice immunized with vaccines adjuvanted with alum
or FA. These results were particularly relevant since alum still rep-
resents the ﬁrst adjuvant choice for human vaccines. The rather
low anti-NS1 antibody responses elicited in mice immunized with
alum was  not attributed to a defective binding of NS1 to the salt
matrix and may  reﬂect an inherent feature of the antigen. Although
mice immunized with FA and NS1 elicited strong anti-NS1 anti-
body responses the use of this adjuvant is not acceptable for a
potential human vaccine due to its reactogenicity. Thus, the demon-
stration that the administration of a non-toxic LT derivative induces
elevated anti-NS1 IgG levels without exacerbated inﬂammatory
reactions represents a relevant contribution for the development of
new protein-based anti-dengue vaccines. Of particular interest was
the observation that anti-NS1 antibodies elicited in mice immu-
nized with LTG33D have shown a clear increase in the avidity to the
viral antigen. Previous studies based on immunization of rhesus
monkeys with inactivated, live attenuated virus or DNA vaccines
encoding the envelope protein showed that protective antibody
responses correlated both with the serum antibody titers and avid-
ity to the target antigen [10]. The ﬁnding that co-administration of
LTG33D may  increase the afﬁnity of the anti-NS1 antibodies to the
target antigen may, therefore, represent an important feature of an
adjuvant incorporated into a subunit-based anti-dengue vaccine.
Protection  induced by NS1-encoding DNA vaccines to the DENV
mouse encephalitis challenge model indicated that both antigen-
speciﬁc B and T cells are important for the mounting of a protective
immune response [14–16]. Under our experimental conditions,
immunization with puriﬁed NS1 in combination with FA or LTG33D
resulted in the activation of B lymphocytes, as evaluated by the
serum anti-NS1 levels, but less efﬁcient activation of cytotoxic
NS1-speciﬁc CD8+ T cell-mediated responses. Activation of CD4+
T helper lymphocytes was inferred indirectly both by the IgG
subclass response as well as by the production of cytokines by
NS1-stimulated splenocytes (IFN- for a Th1-biased pattern and
IL5 for a Th2-biased response). Although IgG subclass response
does not seem to be a particularly relevant parameter regarding
DENV protection, INF- is known to interfere with viral replication
and positively correlates with development of protective immunity
[16,53]. In these two aspects both FA and LTG33D showed similar
behavior after s.c. administration to mice with a more balanced
Th1/Th2 immune response pattern regarding animals immunized
with NS1 and alum. It is conceivable that the partial protective
immunity induced in mice immunized with FA or LTG33D vaccine
formulations is closely related to the circulating NS1-speciﬁc anti-
bodies, in accordance to previous observations [12,13,20,21]. More
proper evaluation of the protective role of anti-NS1 T cell responses,
particularly those involving activation of cytotoxic responses, will
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equire the development of protein-based vaccines with improved
ffect on the induction of CD8+ T cell-dependent responses or the
esting of more complex vaccine regimens, such as those involving
riming with NS1-encoding DNA vaccines.
The safety of the vaccine formulation is a major issue for those
orking on the development of anti-dengue vaccines. Although
rotein-based subunit vaccines tend to be safer than vaccines based
n live attenuated or recombinant viruses [3], incorporation of an
djuvant required for induction of better immune response may
esult in undesirable side effects, including strong inﬂammatory
eactions. In addition, previous studies showed that NS1-speciﬁc
ntibodies generated during DENV infection may  cross-react with
ifferent host proteins including proteins exposed on the surface
f platelets and endothelial cells [22–24,54]. In our experimental
onditions, no hepatic damage, exacerbated inﬂammatory reac-
ions and, more relevantly, altered hematological parameters have
een detected in mice immunized with NS1 admixed with LTG33D.
hese results further conﬁrm that LTG33D represents an effective
nd safe vaccine adjuvant, particularly following administrative via
arenteral routes. Further experiments should address the ques-
ion of deleterious effects induced in vaccinated mice following
hallenge with other DENV types.
Collectively the present results demonstrated that anti-DENV
accines based on puriﬁed recombinant NS1 protein adjuvanted
ith a non-toxic LT derivative represent a new and promising alter-
ative for the development of acellular-based dengue vaccines. The
artial protection observed in the mouse lethal encephalitis model
as achieved in a more restrictive condition if compared to pre-
iously reported studies [14–16], where the sham group had a
igniﬁcant survival rate, reﬂecting the protective potential of the
ested vaccine formulation. Moreover, the incorporation of addi-
ional antigens to the vaccine preparation, such as the envelope
rotein or immunogenic domains derived from it, may  improve
he protective immunity induced in vaccinated subjects. Such ideas
re presently under investigation and shall contribute for a bet-
er understanding of the immunological features of an effective
rotein-based anti-dengue vaccine.
cknowledgements
We are grateful for the technical assistance of L.C. Silva and E.G.
artins. This work was supported by FAPESP, FAPERJ and CNPq
rants.
eferences
[1] Guzman MG,  Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue:
a continuing global threat. Nat Rev Microbiol 2010:S7–16.
[2] Gubler DJ, Meltzer M.  Impact of dengue/dengue hemorrhagic fever on the
developing world. Adv Virus Res 1999;53:35–70.
[3]  Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus
vaccine. Nat Rev Microbiol 2007;7:518–28.
[4]  Kanesa-Thasan N, Sun W,  Kim-Ahn G, Van Albert S, Putnak JR, King A, et al.
Safety and immonogenicity of attenuated dengue virus vaccines (Aventis Pas-
teur) in human volunteers. Vaccine 2001;19:3179–88.
[5]  Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, et al. Phase
I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J
Trop Med  Hyg 2003;69:48–60.
[6] Blaney JE, Durbin AP, Murphy BR, Whitehead SS. Development of a live
attenuated dengue virus vaccine using reverse genetics. Virol Immunol
2006;19:10–32.
[7] Rothman AL. Dengue: deﬁning protective versus pathology immunity. J Clin
Invest 2004;113:948–51.
[8]  Azevedo AS, Yamamura AMY, Freire MS,  Trindade GF, Bonaldo M,  Galler R, et al.
DNA vaccines against dengue virus type 2 based on truncate envelope protein
or its domain III. PloS One 2011;6:e205228.[9] Putnak RJ, Coller BA, Voss G, Vaughn DW,  Clements D, Peters I, et al. An evalu-
ation of dengue type 2 inactivated, recombinant subunit, and live-attenuated
vaccine candidates in the rhesus macaque model. Vaccine 2005;23:4442–52.
10] Simmons M,  Prter KR, Hayes CG, Vaughn DW,  Putnak R. Characterization of
antibody responses to combinations of a dengue virus type 2 DNA vaccine
[ 30 (2012) 837– 845
and  two dengue virus type 2 protein vaccines in rhesus macaques. J Virol
2006;80:9577–85.
11]  Lima DM,  Paula SO, Franc¸ a RFO, Palma PVB, Morais FR, Gomez-Ruiz AC, et al. A
DNA vaccine candidate encoding the structural prM/E proteins elicits a strong
immune response and protects mice against dengue-4 virus infection. Vaccine
2011;29:831–8.
12]  Srivastava AK, Putnak JR, Warren RL, Hoke CH. Mice immunized with a dengue
type 2 virus E and NS1 fusion protein made in Escherichia coli are protected
against lethal dengue virus infection. Vaccine 1995;13:1251–8.
13] Zhang  YM,  Hayes EP, McCarty TC, Dubois DR, Summers PL, Eckels KH, et al.
Immunization of mice with dengue structural protein and nonstructural pro-
tein NS1 expressed by baculovirus recombinant induces resistance to dengue
virus encephalitis. J Virol 1988;62:3027–31.
14] Wu S-F, Liao C-L, Lin Y-L, Yeh C-T, Chen L-K, Huang Y-F, et al. Evaluation of
protective efﬁcacy and immune mechanisms of using a non-structural protein
NS1 in DNA vaccine against dengue 2 virus in mice. Vaccine 2003;21:3919–29.
15] Costa SM,  Paes MV,  Barreto DF, Pinhão AT, Barth OM,  Queiroz JLS, et al. Pro-
tection against dengue type 2 virus induced in mice immunized with a DNA
plasmid encoding the non structural 1 (NS1) gene fused to the tissue plasmino-
gen activator signal sequence. Vaccine 2006;24:195–205.
16] Costa SM,  Azevedo AS, Paes MV,  Sarges FS, Freire MS,  Alves AMB. DNA vac-
cines against dengue virus based on the ns1 gene: the inﬂuence of different
signal sequences on the protein expression and its correlation to the immune
response elicited in mice. Virology 2007;358:413–23.
17]  Flamand M,  Megret F, Mathieu M, Leapult J, Rey FA, Deubel V. Dengue
virus type1 nonstructural glycoprotein NS1 is secreted from mammalian
cells as a soluble hexamer in a glycosylation-dependent fashion. J Virol
1999;73:6104–10.
18]  Young PR, Hilditch PA, Bletchly C, Halloran W.  An antigen capture enzyme-
linked immunosorbent assay reveals high levels of the dengue virus protein
NS1 in the sera of infected patients. J Clin Microbiol 2000;38:1053–7.
19] Avirutnan P, Fuchs A, Hauhart RE, Somnuke P, Youn S, Diamond MS,  et al. Antag-
onism of the complement component C4 by ﬂavivirus nonstructural protein
NS1. J Exp Med  2010;4:793–806.
20] Schlesinger JJ, Brandriss MW,  Walsh EE. Protection of mice against dengue 2
virus encephalitis by immunization with the dengue 2 virus non-structural
glycoprotein NS1. J Gen Virol 1987;68:853–7.
21]  Henchal EA, Henchal LS, Schlesinger JJ. Synergistic interactions of anti-NS1
monoclonal antibodies protect passively immunized mice from lethal chal-
lenge with dengue 2 virus. J Gen Virol 1988;69:2101–7.
22]  Chen MC,  Lin CF, Lei HY, Lin SC, Liu HS, Yeh TM,  et al. Deletion of the
C-terminal region of dengue virus nostructural protein 1 (NS1) abolishes
anti-NS1-mediated platelet dysfunction and bleeding tendency. J Immunol
2009;183:1797–803.
23] Lin H-F, Lei H-Y, Shiau A-L, Liu H-S, Yeh T-M, Chen S-H, et al. Endothelial cell
apoptosis induced by antibodies against dengue virus nonstructural protein 1
via production of nitric oxide. J Immunol 2002;169:657–64.
24] Lin C-F, Wan  S-W, Cheng H-J, Lei H-Y, Lin Y-S. Autoimmune pathogenesis in
dengue virus infection. Viral Immunol 2006;19:127–32.
25]  Lin CF, Wan  SW,  Chen MC,  Lin SC, Cheng CC, Chin SC, et al. Liver injury caused
by antibodies against dengue virus nonstructural protein 1 in murine model.
Lab Invest 2008;88:1079–89.
26] Falconar AKI. Antibody responses are generated to immunodominant ELK/KLE-
type motifs on the nonstructural-1 glycoprotein during live dengue virus
infections in mice and humans: implications for diagnosis, pathogenesis, and
vaccine design. Clin Vaccine Immunol 2007;14:493–504.
27]  Falconar AKI. Monoclonal antibodies that bind to common epitopes on the
dengue virus type 2 nonstructural-1 and envelope glycoproteins display weak
neutralizing activity and differentiated responses to virulent strains: implica-
tions for pathogenesis and vaccines. Clin Vaccine Immunol 2008;15:549–61.
28] O’Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant – “the
long and winding road”. Drug Discov Today 2009;14:541–51.
29]  Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to
work. Immunity 2010;33:492–503.
30] O’Hagan DT, Valiante NM.  Recent advances in the discovery and delivery of
vaccine adjuvants. Nat Rev Drug Discov 2003;9:727–35.
31]  Freytag LC, Clements JD. Mucosal adjuvants. Vaccine 2005;23:1804–13.
32] Rappuoli R, Pizza M,  Douce G, Dougan G. Structure and mucosal adjuvantic-
ity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today
1999;11:493–500.
33]  Guidry JJ, Cárdenas L, Cheng E, Clements JD. Role of receptor binding in toxicity,
immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin.
Infect Immun  1997;65:4943–50.
34] Dickinson BL, Clements JD. Dissociation of Escherichia coli heat-labile
enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun
1995;63:1617–23.
35] Zoeteweij JP, Epperson DE, Porter JD, Zhang CX, Frolova OY, Constantinides
AP, et al. GM1  binding-deﬁcient exotoxin is a potent noninﬂamma-
tory  broad spectrum intradermal immunoadjuvant. J Immunol 2006;177:
1197–207.
36]  Amorim JH, Porchia BFMM,  Balan A, Cavalcante RCM, Costa SM,  Alves AMB,
et al. Refolded dengue virus type 2 NS1 protein expressed in Escherichia coli
preserves structural and immunological properties of the native protein. J Virol
Methods 2010;167:186–92.
37] Hotta S. Experimental studies on dengue. I. Isolation, identiﬁcation, and modi-
ﬁcation of the virus. J Infect Dis 1952;90:1–9.
accine
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[53] Schoenborn JR, Wilson CB. Regulation of interferon- during innate and adap-J.H. Amorim et al. / V
38] Irie K, Mohan PM, Sasaguri Y, Putnak R, Padmanabhan R. Sequence anal-
ysis of cloned dengue virus type 2 genome (New Guinea-C strain). Gene
1989;75:197–211.
39]  Warrens AN, Jones MD,  Lechler RI. Splicing by overlap extension by PCR using
asymmetric ampliﬁcation: an improved technique for the generation of hybrid
proteins of immunological interest. Gene 1997;186:29–35.
40]  Rodrigues JF, Mathias-Santos C, Sbrogio-Almeida ME,  Amorim JH, Cabrera-
Crespo J, Balan A, et al. Functional diversity of heat-labile toxins (LT) produced
by enterotoxigenic Escherichia coli (ETEC): differential enzymatic and immuno-
logical activities of LT1 (hLT) AND LT4 (pLT). J Biol Chem 2011;286:5222–33.
41] Schweizer HP. Vectors to express foreign genes and techniques to monitor gene
expression in Pseudomonas. Curr Opin Biotechnol 2001;12:439–45.
42] Tartoff KD, Hobbs CA. Improved media for growing plasmid and cosmid clones,
vol. 9. Bethseda Research Laboratories Focus; 1987. p. 12.
43] Petsch D, Anspach FB. Endotoxin removal from protein solutions. J Biotechnol
2000;76:97–119.
44]  Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 3rd
ed. New York: Cold Spring Harbor Laboratory Press; 1989. pp. 1527–1800.
45] Sbrogio-Almeida MET, Mosca LM,  Massis IA, Abrahamsohn IA, Ferreira LCS.
Host and bacterial factors affecting induction of immune responses to ﬂag-
ellin expressed by attenuated Salmonella vaccine strains. Infect Immun
2004;72:2546–55.
46]  Jang M, Cho I, Callahan P. Adsoption of globular proteins to vaccine adjuvants.
J Biochem Mol  Biol 1997;30:346–51.
[ 30 (2012) 837– 845 845
47]  Erhardt W,  Hebestedt A, Aschenbrenner G, Pichotka B, Blumel G. A comparative
study with various anesthetics in mice (pentobarbitone, ketamine-xylazine,
carfentanyl-etomidate). Res Exp Med  1984;184:159–69.
48]  Gao G, Wang Q, Dai Z, Calcedo R, Sun X, Li G, et al. Adenovirus-based vac-
cines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue
virus that are present in all major serotypes. Hum Gene Ther 2008;19:
927–36.
49] Palzer S, Bailey T, Hartnett C, Grant A, Tsang M,  Kalyuzhny AE. Simulta-
neous detection of multiple cytokines in ELISPOT assays. Methods Mol  Biol
2005;302:273–88.
50]  Barber DL, Wherry EJ, Ahmed R. Rapid in vivo killing by memory CD8T Cells. J
Immunol 2003;171:27–31.
51] Bargieri DY, Rosa DS, Lásaro MAS, Ferreira LCS, Soares IS, Rodríguez MM.  Adju-
vant requirement for successful immunization with recombinant derivatives
of Plasmodium vivax merozoite surface protein-1 delivered via the intranasal
route. Mem  Inst Oswaldo Cruz 2007;102:313–7.
52]  Verrastro T, Lorenzi TF, Wendel-Neto S. Hematologia – Hemoterapia. São Paulo:
Atheneu; 1996. pp. 1–200.tive immune responses. Adv Immunol 2007;96:41–101.
54] Falconar AKI, Young PR. Immunoafﬁnity puriﬁcation of native dimer
forms of the ﬂavivirus non-structural glycoprotein NS1. J Virol Methods
1990;30:323–32.
